Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.35 |
| ▸ | RARG | P13631 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12625460 | 0.99 | RARB (0.39) | RARBRARARARGFAAHPTGS2 | |
| SCHEMBL3439571 | 0.99 | RARB (0.39) | RARBRARARARGFAAHPTGS2 | |
| SCHEMBL3439577 | 0.99 | RARB (0.39) | RARBRARARARGFAAHPTGS2 | |
| SCHEMBL14884726 | 0.97 | RARB (0.40) | RARBRARARARGFAAHPTGS2 | |
| SCHEMBL12625470 | 0.97 | RARB (0.40) | RARBRARARARGFAAHPTGS2 | |
| SCHEMBL12624717 | 0.96 | RARB (0.38) | RARBRARARARGFAAHPTGS2 | |
| SCHEMBL3439574 | 0.96 | RARB (0.35) | RARBRARARARGFAAHPTGS2 | |
| SCHEMBL3439576 | 0.96 | RARB (0.35) | RARBRARARARGFAAHPTGS2 | |
| SCHEMBL16789608 | 0.95 | RARB (0.41) | RARBRARARARGFAAHPTGS2 | |
| SCHEMBL12625473 | 0.94 | RARB (0.41) | RARBRARARARGFAAHPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611429-B2 | Liquid crystal medium, optical device and liquid crystal compound | JNC CORPORATION (JP) | 2017-04-04 | — | — | US | disclosed |
| US-20160304784-A1 | LIQUID CRYSTAL MEDIUM, OPTICAL DEVICE AND LIQUID CRYSTAL COMPOUND | JNC CORPORATION (JP) | 2016-10-20 | — | — | US | disclosed |
| US-20160122648-A1 | LIQUID CRYSTAL MEDIUM, OPTICAL DEVICE AND LIQUID CRYSTAL COMPOUND | JNC CORPORATION (JP) | 2016-05-05 | — | — | US | disclosed |
| US-8409673-B2 | Chlorobenzene derivative, optically isotropic liquid crystal medium, and optical device | JNC CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120099039-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120099039-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL DEVICE | CRYAB, CYBA, CCNB1 | RARB 153/4885RARA 564/4885RARG 1973/4885 |
| US-20160304784-A1 | LIQUID CRYSTAL MEDIUM, OPTICAL DEVICE AND LIQUID CRYSTAL COMPOUND | HCN1, PIEZO1, NCS1 | RARB 3448/4885RARA 2757/4885RARG 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.